Asia
BioSpace provides an up-to-date overview of these deals and the projected COVID-19 vaccine doses each company plans to have within the next couple of years.
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
Shanghai-based LianBio raised $310 million in an oversubscribed crossover financing round less than two months after the company launched.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
When Japan’s landmark regenerative medicine legislation took effect in 2014, it opened an entirely new market for biotech innovators. Athersys, a leader in regenerative medicine, seized the opportunity.
The agreement provides exclusive rights to EQRx for CStone’s late-stage immuno-oncology anti-PD-L1 monoclonal antibody sugemalimab and anti-PD-1 CS1003.
South Korea, on the other hand, indicated they would continue their state-run vaccination program because they did not find a direct link between the deaths and the vaccinations.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
PRESS RELEASES